In the last trading session, 1.22 million Akero Therapeutics Inc (NASDAQ:AKRO) shares changed hands as the company’s beta touched -0.17. With the company’s per share price at $21.87 changed hands at -$0.76 or -3.36% during last session, the market valuation stood at $1.53B. AKRO’s last price was a discount, traded about -69.18% off its 52-week high of $37.00. The share price had its 52-week low at $15.32, which suggests the last value was 29.95% up since then. When we look at Akero Therapeutics Inc’s average trading volume, we note the 10-day average is 0.78 million shares, with the 3-month average coming to 643.06K.
Analysts gave the Akero Therapeutics Inc (AKRO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.20. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AKRO as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Akero Therapeutics Inc’s EPS for the current quarter is expected to be -1.14.
Akero Therapeutics Inc (NASDAQ:AKRO) trade information
Instantly AKRO was in red as seen at the end of in last trading. With action -20.88%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -21.39%, with the 5-day performance at -20.88% in the red. However, in the 30-day time frame, Akero Therapeutics Inc (NASDAQ:AKRO) is -27.94% down. Looking at the short shares, we see there were 3.31 million shares sold at short interest cover period of 5.52 days.
The consensus price target for the stock as assigned by Wall Street analysts is 50, meaning bulls need an upside of 56.26% from its current market value. According to analyst projections, AKRO’s forecast low is 50 with 50 as the target high. To hit the forecast high, the stock’s price needs a -128.62% plunge from its current level, while the stock would need to soar -128.62% for it to hit the projected low.
Akero Therapeutics Inc (AKRO) estimates and forecasts
Data shows that the Akero Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -20.33% over the past 6 months, a -37.02% in annual growth rate that is considerably lower than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.03%. The 2025 estimates are for Akero Therapeutics Inc earnings to decrease by -34.94%.
AKRO Dividends
Akero Therapeutics Inc is expected to release its next quarterly earnings report in February.
Akero Therapeutics Inc (NASDAQ:AKRO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.58% of Akero Therapeutics Inc shares while 105.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 111.64%. There are 105.41% institutions holding the Akero Therapeutics Inc stock share, with JANUS HENDERSON GROUP PLC the top institutional holder. As of 2024-06-30, the company held 11.5942% of the shares, roughly 6.88 million AKRO shares worth $161.28 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 9.4197% or 5.59 million shares worth $131.06 million as of 2024-06-30.
Among Mutual Funds, the top two as of Oct 31, 2024 were Vanguard Specialized-Health Care Fund and Janus Henderson Global Life Sciences Fund . With 4.4 shares estimated at $96.25 million under it, the former controlled 6.31% of total outstanding shares. On the other hand, Janus Henderson Global Life Sciences Fund held about 2.89% of the shares, roughly 2.02 shares worth around $44.17 million.
